CO2021007668A2 - Producto del compuesto activo carbamato de metil {4,6-diamino-2-[5-fluor-1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-ilo} que tiene propiedades mejoradas, producción y formulación del mismo - Google Patents

Producto del compuesto activo carbamato de metil {4,6-diamino-2-[5-fluor-1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-ilo} que tiene propiedades mejoradas, producción y formulación del mismo

Info

Publication number
CO2021007668A2
CO2021007668A2 CONC2021/0007668A CO2021007668A CO2021007668A2 CO 2021007668 A2 CO2021007668 A2 CO 2021007668A2 CO 2021007668 A CO2021007668 A CO 2021007668A CO 2021007668 A2 CO2021007668 A2 CO 2021007668A2
Authority
CO
Colombia
Prior art keywords
product
fluorobenzyl
pyrazolo
pyrimidin
diamino
Prior art date
Application number
CONC2021/0007668A
Other languages
English (en)
Spanish (es)
Inventor
Guido Becker
Michal Sowa
Peter Fey
Joerg Brockob
Markus Longerich
Heike Neumann
Original Assignee
Adverio Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adverio Pharma Gmbh filed Critical Adverio Pharma Gmbh
Publication of CO2021007668A2 publication Critical patent/CO2021007668A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CONC2021/0007668A 2018-12-17 2021-06-11 Producto del compuesto activo carbamato de metil {4,6-diamino-2-[5-fluor-1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-ilo} que tiene propiedades mejoradas, producción y formulación del mismo CO2021007668A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18213115 2018-12-17
PCT/EP2019/085255 WO2020126983A1 (en) 2018-12-17 2019-12-16 Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate active compound product having improved properties, production and formulation thereof

Publications (1)

Publication Number Publication Date
CO2021007668A2 true CO2021007668A2 (es) 2021-07-19

Family

ID=64744472

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0007668A CO2021007668A2 (es) 2018-12-17 2021-06-11 Producto del compuesto activo carbamato de metil {4,6-diamino-2-[5-fluor-1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-ilo} que tiene propiedades mejoradas, producción y formulación del mismo

Country Status (19)

Country Link
US (1) US12172996B2 (https=)
EP (1) EP3898624A1 (https=)
JP (1) JP7529667B2 (https=)
KR (1) KR102872983B1 (https=)
CN (1) CN113207290B (https=)
AR (1) AR116912A1 (https=)
AU (1) AU2019409269B2 (https=)
BR (1) BR112021009122A2 (https=)
CA (1) CA3123360A1 (https=)
CL (1) CL2021001580A1 (https=)
CO (1) CO2021007668A2 (https=)
IL (1) IL283976B2 (https=)
JO (1) JOP20210155B1 (https=)
MX (1) MX2021007090A (https=)
PE (1) PE20211593A1 (https=)
SG (1) SG11202104953VA (https=)
TW (1) TWI830835B (https=)
UA (1) UA129677C2 (https=)
WO (1) WO2020126983A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI830835B (zh) 2018-12-17 2024-02-01 德商亞德維瑞醫藥有限公司 具改善性質之{4,6-二胺基-2-[5-氟-1-(2-氟芐基)-1H-吡唑並[3,4-b]吡啶-3-基]嘧啶-5-基}胺基甲酸甲酯活性化合物產物、其製造及調配物
EP4099987B1 (en) 2020-02-03 2025-03-12 Adverio Pharma GmbH Nanoformulations of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
EP3925953A1 (en) 2020-06-16 2021-12-22 Adverio Pharma GmbH Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
WO2025114276A1 (en) 2023-12-01 2025-06-05 Krka, D.D., Novo Mesto Solid oral composition comprising vericiguat

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2745813B1 (fr) 1996-03-07 1998-05-07 Rhone Poulenc Chimie Agglomerats spheriques d'acide 10-phenothiazinylpropanoique et leur procede de preparation
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
PL2604608T3 (pl) 2009-11-27 2016-02-29 Adverio Pharma Gmbh Sposób wytwarzania {4,6-diamino-2-[1-(2-fluorobenzylo)-1H-pirazolo[3,4-b]pirydyn-3-ylo]pirymidyn-5-ylo}metylokarbaminianu metylu
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
ES2603028T3 (es) * 2011-11-25 2017-02-23 Adverio Pharma Gmbh Procedimiento para la preparación de (Z)-alfa-fluoro-beta-amino-acrilaldehídos sustituidos
MX2015010725A (es) * 2013-02-21 2016-05-31 Adverio Pharma Gmbh Formas de metil {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato.
PL2792682T3 (pl) 2013-04-19 2017-04-28 Zach System Sposób wytwarzania stałej postaci octanu abirateronu
WO2016113415A1 (en) * 2015-01-16 2016-07-21 Sandoz Ag Process for the preparation of riociguat essentially free from genotoxic impurities
WO2017025981A1 (en) * 2015-08-13 2017-02-16 Msn Laboratories Private Limited Process for the preparation of methyl 4,6-diamino-2-[l-(2-fhiorobenzvr)-lh-pyrazolo i3,4-blpvridin-3-vn-5-pyrimidinyl(methvl)carbamate and its polymorphs thereof
TWI830835B (zh) 2018-12-17 2024-02-01 德商亞德維瑞醫藥有限公司 具改善性質之{4,6-二胺基-2-[5-氟-1-(2-氟芐基)-1H-吡唑並[3,4-b]吡啶-3-基]嘧啶-5-基}胺基甲酸甲酯活性化合物產物、其製造及調配物
CN113272286B (zh) 2019-01-22 2024-04-16 阿德弗里奥药品有限责任公司 制备4-(2,2,3,3-四氟丙基)吗啉的方法
EP4099987B1 (en) * 2020-02-03 2025-03-12 Adverio Pharma GmbH Nanoformulations of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
EP3925953A1 (en) * 2020-06-16 2021-12-22 Adverio Pharma GmbH Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate

Also Published As

Publication number Publication date
MX2021007090A (es) 2021-08-11
PE20211593A1 (es) 2021-08-18
CL2021001580A1 (es) 2021-12-03
SG11202104953VA (en) 2021-06-29
JOP20210155B1 (ar) 2025-10-01
AU2019409269A1 (en) 2021-06-03
JP7529667B2 (ja) 2024-08-06
IL283976B1 (en) 2024-12-01
TW202039488A (zh) 2020-11-01
IL283976B2 (en) 2025-04-01
CN113207290A (zh) 2021-08-03
JOP20210155A1 (ar) 2023-01-30
EP3898624A1 (en) 2021-10-27
KR102872983B1 (ko) 2025-10-17
BR112021009122A2 (pt) 2021-08-10
US20220048907A1 (en) 2022-02-17
UA129677C2 (uk) 2025-07-02
WO2020126983A1 (en) 2020-06-25
IL283976A (en) 2021-07-29
CA3123360A1 (en) 2020-06-25
JP2022515376A (ja) 2022-02-18
AR116912A1 (es) 2021-06-23
AU2019409269B2 (en) 2025-04-03
TWI830835B (zh) 2024-02-01
CN113207290B (zh) 2024-04-09
KR20210104703A (ko) 2021-08-25
US12172996B2 (en) 2024-12-24

Similar Documents

Publication Publication Date Title
CO2021007668A2 (es) Producto del compuesto activo carbamato de metil {4,6-diamino-2-[5-fluor-1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-ilo} que tiene propiedades mejoradas, producción y formulación del mismo
CL2018003323A1 (es) Piridinas sustituidas con heteroarilo y métodos de uso.
PH12018502516B1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
CL2019001369A1 (es) Composición farmacéutica para prevenir o tratar el cáncer de mama, incluido el polimorfo cristalino del hexoxido tetraarsenico y el método para producirlo.
MX2014013879A (es) Particula encapsulada.
PH12019500586A1 (en) Pyrazolo [1,5-a] pyridine derivatives and their use as pesticides
ECSP17011672A (es) Formulación en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
UY36544A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
MX372673B (es) Un inhibidor de btk para usarse en el tratamiento de penfigo y sales y formas sólidas del mismo.
MX2020012520A (es) Macrociclos con grupos p2' heterociclicos como inhibidores del factor xia.
EA201791066A1 (ru) Твердые формы ингибитора ask1
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
MX2019012815A (es) Proceso para la preparacion de compuestos de 2,3-dihidrotiazolo[3, 2-a]pirimidin-4-io opticamente activo.
AR100818A1 (es) N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
CO2018007278A2 (es) Derivados de ácido aminobenzoico metaazacíclico como antagonistas de la integrina pan
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
NI202000029A (es) Amidas de imidazopiridina sustituidas y su uso
DOP2018000083A (es) NUEVOS DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
AR105203A1 (es) Formulación oral sólida que contiene irinotecán y método de preparación de la misma
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
BR112018007358A2 (pt) derivados de 1,4-dicarbonil-piperidila